Showing 4431-4440 of 5771 results for "".
- Neurotech Pharmaceuticals Appoints John Pollack, MD, as Chief Medical Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-john-pollack-md-as-chief-medical-officer/2478549/Neurotech Pharmaceuticals announced that John Pollack, MD, has been appointed to the position of Chief Medical Officer (CMO). Dr. Pollack’s responsibilities will include the execution of clinical studies, patient safety, and the management of Medical Affairs; supporting the required regulatory su
- Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda in the European Unionhttps://modernod.com/news/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-roclanda-in-the-european-union/2478543/Aerie Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.0
- AstraZeneca’s Calquence Fails to Help Patients Hospitalized With COVID-19 Respiratory Symptomshttps://modernod.com/news/astrazenecas-calquence-fails-to-help-patients-hospitalized-with-covid-19-respiratory-symptoms/2478544/AstraZeneca announced that the phase 2 CALAVI studies investigating the addition of Calquence (acalabrutinib) to best supportive care (BSC) in patients hospitalized with respiratory symptoms of COVID-19 failed to meet their primary efficacy endpoint. Results showed that the BTK inhibitor did not
- Lumenis Launches Digital Duet SLT-YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/Lumenis announced the launch of the Digital Duet SLT-YAG platform. The Digital Duet, which Lumenis describes as the first digital SLT-YAG system on the market, improves glaucoma treatment and posterior capsulotomy with the introduction of advanced digital and connectivity capabilities—rede
- Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Material Recycled Through One By One Recycling Programhttps://modernod.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016. The program, made possible through a collaboration with TerraCycle, a leader in the collection and repurposing
- Stoke Therapeutics Nominates Next Preclinical Target in Genetic Eye Diseasehttps://modernod.com/news/stoke-therapeutics-nominates-next-preclinical-target-in-genetic-eye-disease/2478539/Stoke Therapeutics announced the nomination of OPA1 as its second preclinical candidate. “Based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target,” Edward M. Kaye, MD, Chief Executive Offi
- Zeiss Presents Integrated Workflow Advancements at AAOhttps://modernod.com/news/zeiss-presents-integrated-workflow-advancements-at-aao/2478534/The Medical Technology segment of Zeiss will present its latest integrated diagnostic and surgical advancements at the 2020 American Academy of Ophthalmology’s (AAO) Annual Meeting taking place virtually from Nov. 13-15. Zeiss will also be hosting multiple indu
- Leo Lens Pharma Achieves FDA IND Submission and Seed Round Fundraisinghttps://modernod.com/news/leo-lens-pharma-achieves-fda-ind-submission-and-seed-round-fundraising/2478530/Leo Lens Pharma announced the achievement of two milestones: the filing of the FDA’s investigational new drug (IND) application for its lead asset, a proprietary drug-eluting, comfort-enhancing contact lens to treat patients suffering from primary open-angle glaucoma or ocular hy
- EU Seals Deal For Up to 300 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/eu-seals-deal-for-up-to-300-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478528/The European Commission on Wednesday said it has finalized an advance purchase agreement with Pfizer and BioNTech for the initial supply of 200 million doses of their experimental COVID-19 vaccine, with an option to request up to a 100 million more. The announcement comes days after the companies
- New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO Virtualhttps://modernod.com/news/new-data-for-thyroid-eye-disease-treatment-tepezza-to-be-presented-at-aao-virtual/2478527/Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) data will be presented at the American Academy of Ophthalmology Annual Meeting, Nov. 13-15, 2020. Tepezza is the first and only medicine approved by the FDA for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and v